Fesoterodine: Difference between revisions
m (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +)) |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
Line 5: | Line 5: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
Revision as of 17:24, 4 September 2012
WikiDoc Resources for Fesoterodine |
Articles |
---|
Most recent articles on Fesoterodine Most cited articles on Fesoterodine |
Media |
Powerpoint slides on Fesoterodine |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Fesoterodine at Clinical Trials.gov Clinical Trials on Fesoterodine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Fesoterodine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Fesoterodine Discussion groups on Fesoterodine Patient Handouts on Fesoterodine Directions to Hospitals Treating Fesoterodine Risk calculators and risk factors for Fesoterodine
|
Healthcare Provider Resources |
Causes & Risk Factors for Fesoterodine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
The antimuscarinic Fesoterodine is a drug developed by Schwarz Pharma AG to treat Overactive bladder syndrome.[1] It was recommended for approval by the European Medicines Agency in February 2007, but is not yet available for use.[citation needed]
References
- ↑ "Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder - Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006. Check date values in:
|date=
(help)